COVID-19 vaccine available in March

22 February 2024 - Joint media release with Health New Zealand. ...

Read more →

Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease

18 January 2024 - NICE has published additional draft guidance on the use of remdesivir and the combination of tixagevimab ...

Read more →

NICE issues draft guidance for use of remdesivir and also for tixagevimab-cilgavimab for treatment of COVID-19

18 January 2024 - Draft guidance for public consultation has been published by NICE. ...

Read more →

1.4 million more people at risk of severe COVID-19 to have access to antiviral Paxlovid

11 January 2024 - A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be ...

Read more →

Future supply of new COVID-19 vaccines confirmed

20 December 2023 - A vaccine to combat the newer strains of COVID-19 has been approved and will be available ...

Read more →

Evolving our approach to COVID-19 vaccines and treatments

6 December 2023 - As New Zealand’s response to the COVID-19 pandemic has evolved, so has ours. ...

Read more →

Access to COVID-19 anti-viral treatments widened for more people at risk

20 September 2023 - PHARMAC is widening access to COVID-19 anti-virals to people who are vulnerable to severe infection from ...

Read more →

COVID-19 vaccine contract summary

18 September 2023 - The Ministry of Health has released a summary of the New Zealand Government’s procurement process for ...

Read more →

PHARMAC calls for applications from the suppliers of vaccines that protect against COVID-19

16 August 2023 - PHARMAC is interested to hear from pharmaceutical suppliers who manufacture vaccines that protect against COVID-19 and ...

Read more →

PHARMAC considers access criteria for COVID-19 anti-viral treatments

1 August 2023 - PHARMAC is consulting on changes to the access criteria for all COVID-19 anti-viral treatments to include ...

Read more →

Molnupiravir will remain available for people who need it

27 July 2023 - PHARMAC has confirmed today that molnupiravir will remain available as a treatment to protect against infection ...

Read more →

Tixagevimab and cilgavimab for the prevention of COVID-19 disease

14 June 2023 - NICE has published final evidence-based recommendations on the use of tixagevimab and cilgavimab (Evusheld) for the ...

Read more →

Nirmatrelvir and ritonavir for treating COVID-19

4 May 2023 - NICE is conducting a partial rapid review of TA878. ...

Read more →

PHARMAC seeking feedback on the COVID-19 anti-viral molnupiravir

4 April 2023 - PHARMAC are consulting on the role of molnupiravir in New Zealand’s portfolio of COVID-19 treatments.  ...

Read more →

Expanded access to subsidised oral antiviral Paxlovid and other COVID-19 supports

30 March 2023 - From 1 April, more than 160,000 people aged 60 to 69 will have access to the ...

Read more →